Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Price History  |  Ratios  |  Insiders

Stock Quote Today & Recent News Milestone Pharmaceuticals Inc MIST

Healthcare Biotechnology
Milestone Pharmaceuticals Inc., a biopharmaceutical company, focuses on the development and commercialization of cardiovascular medicines in the United States and Canada. It offers CARDAMYST (etripamil) nasal spray, a prescription medication for the conversion of acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm in adults. The company is also... see more

Current News (NDAQ:MIST)

Milestone Pharmaceuticals to Present at the H.C. Wainwright 4th Annual BioConnect Investor Conference at NASDAQ

GlobeNewswire 4 days ago

Milestone Pharmaceuticals Announces First Quarter 2026 Financial Results and Provides Corporate Update

GlobeNewswire 6 days ago

Milestone Pharmaceuticals to Announce First Quarter 2026 Financial Results on May 13, 2026

GlobeNewswire 13 days ago

Milestone Pharmaceuticals Announces RESET-PSVT Registry to Generate Real-World Evidence on CARDAMYST(TM) (etripamil) Nasal Spray in Patients With PSVT

GlobeNewswire April 10, 2026

Milestone Pharmaceuticals to Present at the 25th Annual Needham Virtual Healthcare Conference

GlobeNewswire April 7, 2026

Milestone Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

GlobeNewswire April 2, 2026

Milestone Pharmaceuticals Announces that CARDAMYST(TM) (etripamil) Nasal Spray is Available on Express Scripts Commercial National Formularies

GlobeNewswire March 31, 2026

Milestone Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Update on the Commercial Launch of CARDAMYST(TM) (etripamil) Nasal Spray for the Treatment of PSVT

GlobeNewswire March 20, 2026

Milestone Pharmaceuticals to Present Data on CARDAMYST(TM) (etripamil) Nasal Spray at the 2026 American College of Cardiology Annual Scientific Session

GlobeNewswire March 16, 2026
View More News ››

Opinion & Analysis (NDAQ:MIST)

No current opinion is available.
View More Opinion ››

Bullboard Posts (NDAQ:MIST)

Buy buddy buy.

Otherwise FOMO for you fellas out there today anyway
coolfooldumbguy - December 15, 2025

does 1.50 buy the common share and the two warrants?

Many times these offerings include warrants and you pay for that warrant when you exercise it...the way this is written it says share and...
furward - July 14, 2025

Sell buddy sell.

Otherwise rug pull begins for shareholders today anyway
coolfooldumbguy - July 11, 2025
View more Bullboard ››

Playboy Inc.

Playboy Inc.

Playboy, Inc. operates as a pleasure and leisure company in the United States, Australia, China, the United Kingdom, and ...
View More »

Podcasts